Evaluation of combination therapies with colistin in an experimental mouse pneumonia model induced by carbapenem-resistant Acinetobacter baumannii strain

被引:0
作者
Unal, Onur [1 ,5 ]
Kaya, Onur [1 ]
Ozturk, Tuba [2 ]
Cetin, Emel Sesli [3 ]
Gonen, Ibak [4 ]
Temel, Esra Nurlu [1 ]
Akcam, Fusun Zeynep [1 ]
机构
[1] Suleyman Demirel Univ, Fac Med, Dept Infect Dis & Clin Microbiol, Isparta, Turkiye
[2] Isparta City Hosp, Lab Med Microbiol, Isparta, Turkiye
[3] Suleyman Demirel Univ, Fac Med, Dept Med Microbiol, Isparta, Turkiye
[4] Istanbul Aydin Univ, Dept Infect Dis & Clin Microbiol, Istanbul, Turkiye
[5] Suleyman Demirel Univ, Fac Med, Dept Infect Dis, Isparta, Turkiye
关键词
A; baumannii; carbapenem-resistant; colistin; experimental; pneumonia; EXTENSIVELY DRUG-RESISTANT; INFECTIOUS-DISEASES SOCIETY; GRAM-NEGATIVE BACTERIA; IN-VITRO ACTIVITIES; ANTIMICROBIAL COMBINATIONS; ANTIBIOTIC COMBINATIONS; COMPARATIVE EFFICACY; OPEN-LABEL; TIGECYCLINE; SULBACTAM;
D O I
10.1111/fcp.12891
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The treatment options are limited in Acinetobacter baumannii infections. In this study, the effectiveness of colistin monotherapy and combinations of colistin with different antibiotics were investigated in an experimental pneumonia model induced by carbapenem-resistant A. baumannii strain. Mice in the study were divided into five groups as control (no treatment), colistin monotherapy, colistin + sulbactam, colistin + imipenem, and colistin + tigecycline combinations. The modified experimental surgical pneumonia model of Esposito and Pennington was applied to all groups. The presence of bacteria in blood and lung samples was investigated. Results were compared. In blood cultures, while there was no difference between the control and colistin groups, there was a statistical difference between the control and the combination groups (P = 0.029). When the groups were compared in terms of lung tissue culture positivity, there was a statistical difference between the control group and all treatment groups (colistin, colistin + sulbactam, colistin + imipenem, and colistin + tigecycline) (P = 0.026, P < 0.001, P < 0.001, and P = 0.002, respectively). The number of microorganisms that grew in the lung tissue was found to be statistically significantly lower in all treatment groups in comparison with the control group (P = 0.001). Both monotherapy and combination therapies of colistin were found to be effective in the treatment of carbapenem-resistant A. baumannii pneumonia, but the superiority of combination therapies over colistin monotherapy has not been demonstrated.
引用
收藏
页码:816 / 823
页数:8
相关论文
共 46 条
  • [1] Akcam FZ, 2007, J CHEMOTHERAPY, V19, P230
  • [2] Altuncekic A., 2009, YENI YENIDEN GUNDEME, P123
  • [3] [Anonymous], 2022, M10032ED CLSI
  • [4] Polymyxin combination therapy for multidrug-resistant, extensively-drug resistant, and difficult-to-treat drug-resistant gram-negative infections: is it superior to polymyxin monotherapy?
    Ardebili, Abdollah
    Izanloo, Ahdieh
    Rastegar, Mostafa
    [J]. EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2023, 21 (04) : 387 - 429
  • [5] Mechanisms of Action of Carbapenem Resistance
    Aurilio, Caterina
    Sansone, Pasquale
    Barbarisi, Manlio
    Pota, Vincenzo
    Giaccari, Luca Gregorio
    Coppolino, Francesco
    Barbarisi, Alfonso
    Passavanti, Maria Beatrice
    Pace, Maria Caterina
    [J]. ANTIBIOTICS-BASEL, 2022, 11 (03):
  • [6] Colistin vs. the combination of colistin and rifampicin for the treatment of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia
    Aydemir, H.
    Akduman, D.
    Piskin, N.
    Comert, F.
    Horuz, E.
    Terzi, A.
    Kokturk, F.
    Ornek, T.
    Celebi, G.
    [J]. EPIDEMIOLOGY AND INFECTION, 2013, 141 (06) : 1214 - 1222
  • [7] Ayobami Olaniyi, 2019, Emerg Microbes Infect, V8, P1747, DOI 10.1080/22221751.2019.1698273
  • [8] Bennett J.E., 2019, MANDELL DOUGLAS BENN, V9th
  • [9] In vitro activities of tigecycline (GAR-936) against recently isolated clinical bacteria in Spain
    Betriu, C
    Rodríguez-Avial, I
    Sánchez, BA
    Gómez, M
    Alvarez, J
    Picazo, JJ
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (03) : 892 - 895
  • [10] Are we doing enough to contain Acinetobacter infections
    Brooks, SE
    Walczak, MA
    Hameed, R
    [J]. INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 2000, 21 (05) : 304 - 304